Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
November 19, 2022

New Drug Evaluations

The Committee reviewed the following new drugs:

A. **Furoscix® (furosemide subcutaneous injection by on-body infusor)** scPharmaceuticals
B. **Imjudo® (tremelimumab-actl intravenous infusion)** AstraZeneca
C. **Lytgobi® (futibatinib tablets)** Taiho Pharmaceuticals
D. **Pedmark® (sodium thiosulfate intravenous infusion)** Fennec
E. **Relyvrio™ (sodium phenylbutyrate and taurursodiol powder for oral suspension)** Amylyx
F. **Rolvedon™ (eflapegrastim-xnst subcutaneous injection)** Spectrum
G. **Skysona® (elivaldogene autotemcel intravenous infusion)** Bluebird Bio
H. **Sotyktu™ (deucravacitinib tablets)** Bristol Myers Squibb
I. **Tecvayli™ (teclistamab-cqyv subcutaneous injection) J**anssen Biotech
J. **Xenpozyme™ (olipudase alfa-rpcp intravenous infusion)** Genzyme

New Biosimilar

The Committee reviewed the following biosimilar:

A. **Vegzelma™ (bevacizumab-adcd intravenous infusion)** Celltrion

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions:

A. **Ponvie™ (aprepitant intravenous injection)** Heron Therapeutics
B. **Paclitaxel protein-bound particles intravenous infusion** (HBT Labs)

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: See product inserts for specific wording.

A. **ABoostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed)** GlaxoSmithKline – New indication for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.
B. **Cotellic® (cobimetinib tablets)** Genentech – New indication for the treatment of histiocytic neoplasms as a single agent in adults.
C. **Dupixent® (dupilumab subcutaneous injection)** Sanofi/Regeneron – New indication for the treatment of prurigo nodularis in adults.
D. **Firdapse® (amifampridine tablets)** Catalyst – Expanded age indication to include pediatric patients ≥ 6 years of age. Firdapse is now indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients ≥ 6 years of age.

E. **Imfinzi® (durvalumab intravenous infusion)** AstraZeneca – New indication for use in combination with Imjudo® (tremelimumab-actl intravenous infusion) for the treatment of unresectable hepatocellular carcinoma in adults.
F. **Lyumjev™ (insulin lispro-aabc subcutaneous or intravenous injection)** Lilly – Expanded age indication to include pediatric patients. Lyumjev is now indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
G. **Oxlumo® (lumasiran subcutaneous injection)** Alnylam – Expanded indication to include lowering of plasma oxalate levels in adult and pediatric patients with primary hyperoxaluria type 1 (PH1). Oxlumo is now indicated for the treatment of PH1 to lower urinary and plasma oxalate levels in pediatric and adult patients.
H. **Retevmo® (selpercatinib capsules)** Lilly – New indication for locally advanced or metastatic solid tumors in adults with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
I. **Rinvoq® (upadacitinib extended-release tablets)** AbbVie – New indication for the treatment of active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor inhibitors.
J. **Vemlidy® (tenofovir alafenamide tablets)** Gilead – Expanded age indication to include pediatric patients ≥ 12 years of age. Vemlidy is now indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients ≥ 12 years of age with compensated liver disease.
K. **Zejula® (niraparib capsules)** GlaxoSmithKline – Removal of indication for the treatment of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in adults who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency positive status, defined by either a deleterious or suspected deleterious breast cancer susceptibility gene mutation, or genomic instability and who have progressed more than 6 months after response to the last platinum-based chemotherapy.